Option Care Health Surges 34% on $5.8B CD&R-McKesson Buyout
CD&R and McKesson struck a $5.8B deal to acquire Option Care Health, sending OPCH shares soaring 34% in a major home-infusion sector shakeup.
Option Care Health shares rocketed 34% after Clayton, Dubilier & Rice and McKesson agreed to acquire the home-infusion therapy company in a deal valued at approximately $5.8 billion, marking one of the largest healthcare-services transactions of the year. The announcement sent OPCH stock surging as investors priced in the takeover premium, a classic signal that the market views the bid price as credible and near-final.
The partnership between private-equity heavyweight CD&R and pharmaceutical distribution giant McKesson is a notable strategic alignment. McKesson's existing footprint in drug distribution gives the combined entity a natural supply-chain advantage over Option Care Health's infusion operations, potentially unlocking cost synergies that neither buyer could easily capture alone.
Read more S&P 500 Hits Intraday Record as Tech Leads Market Comeback →
Option Care Health is one of the nation's largest independent providers of home and alternate-site infusion services, a segment that has drawn intensifying investor interest as payers and patients alike push for care to migrate out of expensive hospital settings. The $5.8 billion valuation reflects the premium placed on scaled, tech-enabled home-care platforms in the current healthcare landscape.
The deal underscores a broader consolidation wave sweeping through specialty and home-based care, as private equity and strategic acquirers race to control the infrastructure of out-of-hospital treatment. Regulatory scrutiny of healthcare mergers remains an open variable, though the complementary — rather than directly competing — nature of McKesson's distribution business and OPCH's care-delivery model may ease antitrust concerns.
Continue reading at SeekingAlpha.
